Literature DB >> 35117515

Retrospective study of risk factors for colorectal adenomas and non-adenomatous polyps.

Guanqun Chao1, Yue Zhu1, Lizheng Fang1.   

Abstract

BACKGROUND: To clarify the risk factors of colorectal adenomas and non-adenomatous polyps by retrospective analysis.
METHODS: Data were obtained from subjects who underwent health examination in the Health Promotion Centre of Sir Run Run Shaw Hospital of Zhejiang University from January 2016 to December 2018, and all of them completed colonoscopies. Statistical analysis was performed using R software.
RESULTS: A total of 721 subjects were included in the analysis, of whom 58 (8.0%) were diagnosed as non-adenomatous polyps, 115 (16.0%) as adenomas, 3 (0.4%) as neuroendocrine neoplasms or adenocarcinomas. The gender ratio and prevalence of fatty liver in the non-adenomatous polyp group were different from that in the control group, and age, body mass index (BMI), waist circumference, blood glucose, serum uric acid, triglyceride, alanine transaminase and creatinine levels were higher, while the level of high-density lipoprotein was lower than control group (P<0.05). The sex ratio in the adenoma group was different from that in the control group, age, BMI, waist circumference, glycosylated hemoglobin, serum uric acid, triglyceride and creatinine levels were higher (P<0.05). Age was a risk factor for non-adenomatous polyps. Male and age were risk factors for adenomas.
CONCLUSIONS: Age, body weight, waist circumference, blood lipid and blood glucose are related to the high incidence of colorectal adenomas and non-adenomatous polyps; fatty liver is related to the high incidence of colorectal non-adenomatous polyps; age is a risk factor for non-adenomatous polyps; age and male are risk factors for colorectal adenomas. 2020 Translational Cancer Research. All rights reserved.

Entities:  

Keywords:  Colorectal adenoma (CRC); fatty liver; non-adenomatous polyp; risk factor

Year:  2020        PMID: 35117515      PMCID: PMC8797785          DOI: 10.21037/tcr.2020.01.69

Source DB:  PubMed          Journal:  Transl Cancer Res        ISSN: 2218-676X            Impact factor:   1.241


Introduction

Colorectal cancer (CRC) is the second most common malignancy in the world with a high mortality rate (1). Multiple guidelines indicate that people over age 50 with no symptoms should be screened for colon cancer (2,3). Due to mutations in oncogenes and tumor suppressor genes, most CRCs originate from benign adenomas and develop into malignant tumors after more than 10 years (4). Colorectal adenomas and other types of proliferative polyps are considered precancerous lesions in CRC (5). In recent decades, the incidence of CRC is on the rise worldwide (6). Therefore, how to detect and treat the precancerous lesions of CRC early is an important clinical problem that needs to be solved. The study found that age, family history, gender, race, smoking and other factors were associated with CRC (7). The risk of CRC was significantly higher in diabetics than in other cancers (8). The increased concentration of serum insulin and insulin-like growth factor in patients with insulin resistance may promote the growth of precancerous lesions in CRC, thus increasing the possibility of malignant tumor (9). Insulin can stimulate colorectal cell proliferation and increase the biological activity of insulin-like growth factor-1 (IGF-1), thereby promoting cell mitosis and anti-apoptosis (10). Recent studies suggest that the presence and severity of nonalcoholic fatty liver disease may be associated with the risk of CRC or adenoma (11). Nonalcoholic fatty liver disease with advanced fibrosis may be a risk factor for colorectal adenomas compared with nonalcoholic fatty liver disease without fibrosis (12). Adenoma and advanced neoplasia are associated with age, with twice as many cases occurring over age 45 (13). We will further clarify the risk factors of colorectal adenomas and hyperplastic polyps by retrospective analysis of the data of physical examination population, and verify the relationship between non-alcoholic fatty liver disease (NAFLD) and colorectal lesions.

Methods

Data and methods

Data were obtained from subjects who underwent health examination in the Health Promotion Centre of Sir Run Run Shaw Hospital of Zhejiang University from January 2016 to December 2018, and all of them completed colonoscopies (). Exclusion criteria: (I) failed to complete the liver B-ultrasound examination; (II) lack of baseline information (incomplete history or partial test data); (III) patients after intestinal surgery; (IV) polyps and masses found in colonoscopy need pathological biopsy clear, but the patient refused or pathological biopsy data missing.
Figure 1

Subjects’ inclusion process.

Subjects’ inclusion process.

Colonoscopy and biopsy

All selected subjects were examined by an experienced colonoscopist using a video colonoscopy. Participants with colonic polyps were recommended for endoscopic polypectomy and biopsy. Biopsy specimens were examined by an experienced pathologist.

Physical examination data acquisition

When height and weight were measured, the subjects wore light clothes and no shoes. body mass index (BMI) is obtained by dividing weight (kg) by height (m) squared. Waist circumference is the length of one circle around the umbilical level. During the blood pressure measurement, the patient sat quietly for 10 minutes before the blood pressure measurement, and the systolic and diastolic blood pressure of the right upper limb were measured. Blood biochemical indicators, such as total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-c), high-density lipoprotein cholesterol (HDL-c), glycosylated hemoglobin (HbA1c), alanine aminotransferase (ALT), cereal straw aminotransferase (AST), and glutamyl transpeptidase (GGT), were all completed by the hospital laboratory.

Diagnosis and criteria of fatty liver

Abdominal ultrasound was performed on all selected subjects. Abdominal ultrasonography was performed by experienced doctors, and the diagnosis of fatty liver was based on the guidelines for the prevention and treatment of fatty liver disease (2018 edition): B-ultrasonography was the first choice for the imaging diagnosis of fatty liver.

Data analysis

The data were analyzed by R software (version 3.5.1). Measurement data of normal distribution were described in the form of mean standard deviation (±s), measurement data of non-normal distribution were described in the form of median (quartile), and counting data were described in the form of percentage .Student t-test was used for the mean value comparison of measurement data between the two groups of normal distribution, Wilcoxon symbolic rank test was used for the mean value comparison of measurement data between the two groups of normal distribution, and chi-square test was used for the comparison of counting data. Multivariate logistic regression analysis was performed to calculate the ratio (OR value) of age, gender, blood pressure, blood lipid and other factors. The statistical analysis was performed on both sides. When the P value was less than 0.05, it was considered statistically significant.

Results

Demographic and laboratory variables of the studied subjects

Finally, 721 subjects were included in the analysis, of whom 58 (8.0%) were diagnosed as non-adenomatous polyps, 115 (16.0%) as adenomas, 3 (0.4%) as neuroendocrine neoplasms or adenocarcinomas, and the remaining 545 (75.6%) were classified as controls. The gender ratio and prevalence of fatty liver in the non-adenomatous polyp group were different from that in the control group, and the age, BMI, waist circumference, blood glucose, serum uric acid, triglyceride, alanine transaminase and creatinine levels were higher than those in the control group, while the levels of high-density lipoprotein were lower than those in the control group, with statistically significant differences (P<0.05). The sex ratio in the adenoma group was different from that in the control group, with statistically significant differences in age, BMI, waist circumference, glycosylated hemoglobin, serum uric acid, triglyceride and creatinine levels (P<0.05). Waist in the group of adenoma and the adenomatous polyp have differences, the age, BMI, blood pressure, fasting glucose, glycosylated hemoglobin, serum uric acid, triglyceride, total cholesterol, low density lipoprotein cholesterol, high-density lipoprotein cholesterol, alanine aminotransferase, aspartate aminotransferase, urea nitrogen, creatinine and so on had no statistically significant differences ().
Table 1

Demographic and laboratory analysis of adenoma and non-adenomatous polyp groups

FactorControl group (n=545)Non-adenomatous polyp (n=58)Adenoma (n=115)aPbPcP
Male gender330 (60.6%)49 (84.5%)90 (78.3%)<0.001<0.0010.442
Age, years48.8±8.4552.0±5.8751.1±7.66<0.0010.0320.395
BMI, kg/m224.4±3.1526.1±3.3725.2±2.97<0.0010.0060.096
BP, mmHg
   SBP122±14.8123±11.9122±13.70.3470.5930.681
   DBP73.5±11.075.6±8.9375.1±10.20.1050.1430.733
WC, cm85.8±9.8092.3±10.388.4±9.41<0.0010.0090.0157
FBG*, mmol/L5.12 (3.60, 15.8)5.37 (4.20, 13.8)5.32 (4.00, 11.1)0.013<0.0010.879
UA, mg/dL352±90.7381±90.1383±88.00.020<0.0010.882
TG*, mg/dL1.41 (0.380, 17.2)1.64 (0.560, 9.68)1.60 (0.540, 37.7)0.0020.0030.384
TC, mg/dL4.98±0.9374.95±0.8525.13±0.9780.8390.1350.230
HDL, mg/dL1.16±0.2941.02±0.2621.10±0.290<0.0010.0700.069
LDL, mg/dL2.82±0.7622.66±0.7492.80±0.7280.1250.7720.247
ALT*, IU/L21.0 (5.00, 181)27.5 (7.00, 86.0)23.0 (9.00, 79.0)0.0050.1330.113
AST, IU/L20.0 (9.00, 264)23.0 (12.0, 52.0)21.0 (11.0, 82.0)0.0110.0900.294
Fatty liver disease212 (38.9%)33 (56.9%)48 (41.7%)0.0010.6450.085

*, it makes sense between the groups. aP, two-sided P values for the difference between the non-adenomatous polyp group and control group; bP, two-sided P values for the difference between the adenoma group and control group; cP, two-sided P values for the difference between the adenoma group and non-adenomatous polyp group. BP, blood pressure; SBP, systolic blood pressure; DBP, diastolic blood pressure; WC, Waist circumference; FBG, fast blood glucose; SUA, serum Uric acid; TC, total cholesterol; TG, triglycerides; LDL, low density lipoprotein; HDL, high density lipoprotein; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BUN, blood urea nitrogen.

*, it makes sense between the groups. aP, two-sided P values for the difference between the non-adenomatous polyp group and control group; bP, two-sided P values for the difference between the adenoma group and control group; cP, two-sided P values for the difference between the adenoma group and non-adenomatous polyp group. BP, blood pressure; SBP, systolic blood pressure; DBP, diastolic blood pressure; WC, Waist circumference; FBG, fast blood glucose; SUA, serum Uric acid; TC, total cholesterol; TG, triglycerides; LDL, low density lipoprotein; HDL, high density lipoprotein; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BUN, blood urea nitrogen.

Logistic regression analysis of risk factors

In the logistic regression model, male gender, age, BMI, systolic blood pressure, diastolic blood pressure, waist circumference, blood glucose, serum uric acid, triglyceride, total cholesterol, high-density lipoprotein, low-density lipoprotein and liver and kidney function were included in the analysis. Univariate regression analysis showed that gender, age, BMI, abdominal circumference, fasting blood glucose, uric acid, triglyceride level, high-density lipoprotein cholesterol level and fatty liver were risk factors for non-adenomatous polyps. After adjustment of the multivariate model, only age was a risk factor for non-adenomatous polyps. Similarly, univariate regression analysis showed that gender, age, BMI, abdominal circumference, blood glucose, uric acid, triglyceride level, creatinine, and urea nitrogen were risk factors for adenomas. After adjustment of the multivariate model, male and age were risk factors for adenomas ().
Table 2

Risk factors analysis of adenoma group and non-adenomatous polyp group

FactorCrudeAdjusted*
OR95%CIPOR95%CIP
Non-adenomatous polyp
   Male gender3.5481.790–7.858<0.001*2.4161.022–6.1230.051
   Age1.0471.013–1.0820.006*1.0451.009–1.0830.015*
   BMI1.4361.427–1.445<0.001*1.0861.267–1.2860.107
   SBP1.0080.989–1.0260.426
   DBP1.0170.993–1.0430.166
   WC1.0701.040–1.103<0.001*1.0261.539–1.6680.262
   FBG1.2871.096–1.5040.001*1.1331.645–1.7690.174
   SUA1.0031.000–1.0060.019*0.9990.099–1.0030.520
   TG1.2121..058–1.3950.005*1.1020.924–1.2850.230
   TC0.9720.722–1.2980.850
   HDL0.1420.043–0.430<0.001*0.3540.908–1.2580.121
   LDL0.7510.517–1.0790.127
   ALT1.0110.998–1.0230.076
   AST1.0060.985–1.0220.447
   FLD2.0731.203–3.6150.009*0.8240.401–1.6860.595
Adenoma
   Male gender2.3451.479–3.840<0.001*2.0421.018–4.1790.047*
   Age1.0331.008–1.0580.009*1.0361.010–1.0630.007*
   BMI1.0801.014–1.1510.017*1.0620.984–1.1460.120
   SBP1.0040.990–1.0170.609
   DBP1.0130.995–1.0320.163
   WC1.0211.007–1.0500.010*0.9830.954–1.0130.257
   FBG1.2071.035–1.4050.014*1.1140.937–1.3110.198
   SUA1.0041.002–1.006<0.001*1.0020.999–1.0050.197
   TG1.1351.031–1.2780.023*1.0850.986–1.2220.131
   TC1.1790.955–1.4530.123
   HDL0.5070.237–1.0400.717
   LDL0.9620.735–1.2550.777
   ALT1.0030.991–1.0130.651
   AST1.0070.992–1.0220.299
   CR1.0151.002–1.0290.027*0.9990.979–1.0190.908
   BUN1.1240.918–1.372<0.001*0.9400.746–1.1780.593
   FLD1.1250.745–1.6900.571

Crude means only single factor regression analysis without adjusting age, gender and other factors. *, it makes sense between the groups. Gender, age, BMI, central obesity, diabetes, different levels of uric acid, high TC, high TG, high LDL-c, low HDL-c, and abnormal liver function were Adjusted. OR, odds ratio; BMI, body mass index; SUA, serum uric acid; TC, total cholesterol; HDL, high-density lipoproteins; LDL, low-density lipoproteins; LF, liver function.

Crude means only single factor regression analysis without adjusting age, gender and other factors. *, it makes sense between the groups. Gender, age, BMI, central obesity, diabetes, different levels of uric acid, high TC, high TG, high LDL-c, low HDL-c, and abnormal liver function were Adjusted. OR, odds ratio; BMI, body mass index; SUA, serum uric acid; TC, total cholesterol; HDL, high-density lipoproteins; LDL, low-density lipoproteins; LF, liver function.

Discussion

CRC is considered a major public health problem due to its high morbidity and mortality. Recent studies have found that CRC is also increasing in morbidity and mortality among adolescents (14). Because CRC screening rate increased, adenoma early resection, in recent years, adult CRC mortality has been reduced (15). Molecular evidence suggests that CRC may be caused by mixed polyps, in addition to cytologic dysplasia (16). A prospective study found that none of the carriers of polypos-related mutations developed colorectal polyps (17). This shows, although the happening of CRC thinks to be concerned with heredity, but gene is not the main reason that appears CRC pathological change. Our study analyzed patients who completed colonoscopies between 2016 and 2018. In the 721 subjects, 58 (8.0%) were diagnosed as non-adenomatous polyps, 115 (16.0%) as adenomas, 3 (0.4%) as neuroendocrine neoplasms or adenocarcinomas. Compared with the control group, age, BMI, waist circumference, blood glucose, serum uric acid, triglyceride of non-adenomatous polyps group and adenoma group were higher, and HDL was lower in non-adenomatous polyps group, AST was higher in non-adenomatous polyps group as well. Previous studies have shown that metabolic syndrome is associated with CRC and colorectal polyps (18). Studies on colorectal hyperplastic polyps suggest that metabolic syndrome is a high-risk factor (19). Our study showed that blood glucose, serum uric acid and triglyceride levels increased significantly in patients with colonic adenoma and other polyps, this is consistent with the research of other scholars. Current studies suggest that the mechanism may be related to insulin resistance in patients with metabolic syndrome (20). The research showed that older age (≥60), male sex, and higher BMI (≥25) were associated with the development of colorectal adenoma (21). Previous studies have suggested that the presence of metabolic syndrome, or an increase in BMI, is associated with the risk of colorectal adenoma and CRC (22). Our research showed that the higher BMI and higher waist circumference in non-adenomatous polyps group and adenoma group was similar. We further performed a regression analysis of risk factors for colorectal adenomas and non-adenomatous polyps. Age and male gender were the risk factors of colorectal adenomas, and only age was the risk factor of non-adenomatous polyps. There are currently several guidelines on CRC screening published in many countries or organizations, and the guidelines clearly indicate the correlation between age and colon cancer screening, which is consistent with our study that age is an important risk factor. NAFLD is a kind of liver disease without viral hepatitis, drug-induced liver injury, excessive alcohol consumption, hereditary disorders and so on, as a result of its high prevalence it becomes an important public health issue (23). A large Korean population study found a direct association between nonalcoholic fatty liver disease and colorectal adenomas (24). Scholars have pointed out that the formation of colon tumors is related to the severity of fatty liver, but the correlation is not significant under the interference of other factors (25). Non-alcoholic steatohepatitis has also been shown to be associated with a higher incidence of CRC and CRC progression (26). Although it is currently believed that non-alcoholic fatty liver may be related to the occurrence of CRC and colorectal adenoma, there are conflicting opinions, and the causes and mechanisms of its high incidence are still unclear. In this study, it was found that the incidence of fatty liver was significantly increased in the colorectal non-adenomatous polyp group, while there was no significant difference in the adenoma group. At the same time, fatty liver was not considered as a risk factor for colorectal adenomas and non-adenomatous polyps after multivariate regression analysis. The increased incidence of fatty liver indicates that fatty liver is related to the occurrence of colorectal non-adenomatous polyps, which is consistent with the studies of some scholars. However, our analysis failed to prove that fatty liver could be a risk factor for colorectal adenomas and non-adenomatous polyps, for the following reasons: (I) the sample size was limited and there was a large gap between the groups; (II) the selected subjects were located in southeast China, and their living habits, genetic factors, diet, soil and water were different from other countries; (III) similar to previous studies, there were other factors that interfered. Insulin resistance is believed to be an important reason for the increased incidence of CRC in patients with metabolic syndrome (27). In addition, high NLR was associated with increased colorectal adenomatous polyps (28). Thus, inflammatory cytokines such as tumor necrosis factor-α and interleukin-6 and other pro-inflammatory cytokines play a role in colorectal adenomas and carcinomas (29). In addition, nonalcoholic fatty liver disease is thought to be mostly insulin resistant (30). As a result, patients with nonalcoholic fatty liver disease have a higher incidence of colorectal adenomas and cancers. Our study failed to find a correlation between fatty liver and colorectal adenoma, which may be related to the presence of insulin resistance and chronic inflammation in the patients. Our study found that age, weight, waist circumference, blood lipids, blood glucose and other factors were related to colorectal adenomas and non-adenomatous polyps. The incidence of fatty liver in patients with non-adenomatous polyps was significantly increased, while age was a risk factor for non-adenomatous polyps, and age and male were risk factors for colorectal adenomas. To sum up, we suggest that the patients with overweight, abnormal metabolic indicators and fatty liver should pay attention to colonoscopy examination, especially older men, and should have colonoscopy screening regularly.

Conclusions

Age, body weight, waist circumference, blood lipid and blood glucose are related to the high incidence of colorectal adenomas and non-adenomatous polyps; fatty liver is related to the high incidence of colorectal non-adenomatous polyps; age is a risk factor for non-adenomatous polyps; age and male are risk factors for colorectal adenomas.
  30 in total

Review 1.  Obesity and diabetes as prognostic factors in patients with colorectal cancer.

Authors:  Ioannis A Voutsadakis
Journal:  Diabetes Metab Syndr       Date:  2016-12-13

2.  The metabolic syndrome is associated with an increased risk of colorectal polyps independent of plasma homocysteine.

Authors:  Fang-Pei Chen; Hwei-Ming Wang; Feng-Fan Chiang; Chun-Che Lin; Shih-Chien Huang; Yi-Chia Huang
Journal:  Ann Nutr Metab       Date:  2014-06-25       Impact factor: 3.374

3.  Association of colorectal adenoma with components of metabolic syndrome.

Authors:  Byung Chang Kim; Aesun Shin; Chang Won Hong; Dae Kyung Sohn; Kyung Su Han; Kum Hei Ryu; Bum Joon Park; Ji Hyung Nam; Ji Won Park; Hee Jin Chang; Hyo Seong Choi; Jeongseon Kim; Jae Hwan Oh
Journal:  Cancer Causes Control       Date:  2012-03-27       Impact factor: 2.506

Review 4.  The association between nonalcoholic fatty liver disease and risk of colorectal adenoma and cancer incident and recurrence: a meta-analysis of observational studies.

Authors:  Jin Chen; Dongxue Bian; Shufei Zang; Zongxing Yang; Guoyan Tian; Yan Luo; Jing Yang; Beibei Xu; Junping Shi
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2019-02-19       Impact factor: 3.869

5.  Increasing disparities in the age-related incidences of colon and rectal cancers in the United States, 1975-2010.

Authors:  Christina E Bailey; Chung-Yuan Hu; Y Nancy You; Brian K Bednarski; Miguel A Rodriguez-Bigas; John M Skibber; Scott B Cantor; George J Chang
Journal:  JAMA Surg       Date:  2015-01       Impact factor: 14.766

6.  Polyp Resection and Removal Procedures: Insights From the 2017 Digestive Disease Week.

Authors:  Carol Burke; Vivek Kaul; Heiko Pohl
Journal:  Gastroenterol Hepatol (N Y)       Date:  2017-09

Review 7.  Nonalcoholic Fatty Liver Disease and Insulin Resistance: New Insights and Potential New Treatments.

Authors:  Hironori Kitade; Guanliang Chen; Yinhua Ni; Tsuguhito Ota
Journal:  Nutrients       Date:  2017-04-14       Impact factor: 5.717

8.  Liver fibrosis is associated with risk for colorectal adenoma in patients with nonalcoholic fatty liver disease.

Authors:  Min Cheol Kim; Jung Gil Park; Byung Ik Jang; Heon Ju Lee; Won Kee Lee
Journal:  Medicine (Baltimore)       Date:  2019-02       Impact factor: 1.817

9.  Investigation of Insulin-Like Growth Factor-1 (IGF-1), P53, and Wilms' Tumor 1 (WT1) Expression Levels in the Colon Polyp Subtypes in Colon Cancer.

Authors:  Ali Aslan; Havva Erdem; Muruvvet Akcay Celik; Arzu Sahin; Soner Cankaya
Journal:  Med Sci Monit       Date:  2019-07-25

10.  The Fatty Liver Index: A Simple and Accurate Predictor of Colorectal Adenoma in an Average-Risk Population.

Authors:  Eun Young Ze; Beom Jin Kim; Dong Hwan Jun; Jae Gyu Kim; Hyun Kang; Dong Young Lee
Journal:  Dis Colon Rectum       Date:  2018-01       Impact factor: 4.585

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.